Boston Scientific (BSX) Q2 Earnings and Revenues Surpass Estimates

Company Performance - Boston Scientific reported quarterly earnings of $0.75 per share, exceeding the Zacks Consensus Estimate of $0.72 per share, and up from $0.62 per share a year ago, representing an earnings surprise of +4.17% [1] - The company posted revenues of $5.06 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.48%, compared to revenues of $4.12 billion in the same quarter last year [2] - Over the last four quarters, Boston Scientific has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance - Boston Scientific shares have increased approximately 15.5% since the beginning of the year, outperforming the S&P 500's gain of 7.3% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.70 on revenues of $4.85 billion, and for the current fiscal year, it is $2.91 on revenues of $19.5 billion [7] - The outlook for the industry, particularly the Medical - Products sector, is currently in the bottom 30% of Zacks industries, which may impact stock performance [8]